Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06015295 · ClinicalTrials.gov registry record · NA
A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy
A NA study of Brain Metastases, sponsored by M.D. Anderson Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06015295: Recruiting NA study of Brain Metastases, sponsored by M.D. Anderson Cancer Center.
NCT06015295 is a NA study of Brain Metastases that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 20 participants, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (91% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06015295, a NA study of Brain Metastases, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To learn if 18F-Fluciclovine (Axumin) PET-CT scans can be used to better detect brain metastatic lesions in patients who are receiving immunotherapy.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST 18F-Fluciclovine (Axumin)
- DIAGNOSTIC_TEST Pet Scan
Study Locations (1)
Texas
- M D Anderson Cancer Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2024-11-07 |
| Est. Completion | 2028-03-30 |
| Phase | NA |
What NCT06015295 shows while recruiting
NCT06015295 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 213-participant average among 67 other Brain Metastases trials with a reported enrollment target (91% lower).
The record links to 1 condition, with Brain Metastases appearing as the primary indexed condition, and to 2 interventions - of which 18F-Fluciclovine (Axumin) is the first listed.
NCT06015295 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT06015295 about?
NCT06015295 is a clinical study titled "A Pilot Study to Assess the Clinical Utility of 18F-Fluciclovine (Axumin) PET-CT for Detecting True-versus Pseudo-Progression of Brain Metastases on Immunotherapy". To learn if 18F-Fluciclovine (Axumin) PET-CT scans can be used to better detect brain metastatic lesions in patients who are receiving immunotherapy.
What is the current status of trial NCT06015295?
This trial is currently recruiting. It is a NA study. The enrollment target is 20 participants. The study started on 2024-11-07. Estimated completion is 2028-03-30.
What conditions does trial NCT06015295 study?
This clinical trial studies the following conditions: Brain Metastases.
What interventions are being tested in trial NCT06015295?
The interventions under investigation include: 18F-Fluciclovine (Axumin) (DIAGNOSTIC_TEST), Pet Scan (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06015295?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06015295 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Brain Metastases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06015295's enrollment target sits among peer trials
20 51st of 67 higher than 9 of 67 other Brain Metastases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Brain Metastases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Trial of Differential Margins in Single Isocenter Radiosurgery of Brain Metastases
RECRUITING · NA
-
Evaluation of the CONVIVO System
RECRUITING · NA
-
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
RECRUITING · NA
-
REMASTer: REcurrent Brain Metastases After SRS Trial
RECRUITING · NA
-
Development of MRF for Characterization of Brain Tumors After Radiotherapy
RECRUITING · NA
-
MeDex: No Perioperative Dexamethasone in Brain Metastases
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI